A phase II, multicenter, open‐label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active …

N Ruperto, P Quartier, N Wulffraat, P Woo… - Arthritis & …, 2012 - Wiley Online Library
Objective To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human
anti–interleukin‐1β (anti–IL‐1β) antibody, in children with systemic juvenile idiopathic …

A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease

CH Sibley, A Chioato, S Felix, L Colin… - Annals of the …, 2015 - ard.bmj.com
Objective To study efficacy and safety of escalating doses of canakinumab, a fully human
anti-IL-1β monoclonal antibody in the severe cryopyrin-associated periodic syndrome …

Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects …

A Chioato, E Noseda, M Stevens… - Clinical and Vaccine …, 2012 - Am Soc Microbiol
Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in
healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) …

A phase II study to evaluate dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

N Ruperto, P Quartier, N Wulffraat, P Woo… - Arthritis & …, 2012 - oak.novartis.com
Objectives: To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human
anti-interleukin-1β (IL-1β) antibody, in children with systemic juvenile idiopathic arthritis …

Bioequivalence of canakinumab liquid pre-filled syringe and reconstituted lyophilized formulations following 150 mg subcutaneous administration: a randomized study …

A Chioato, E Noseda, L Colin, R Matott… - Clinical drug …, 2013 - Springer
Background Canakinumab is a human anti-interleukin-1beta antibody approved for the
treatment of cryopyrin associated periodic syndrome currently formulated as a lyophilized …

[CITATION][C] Influenza and meningococcal vaccination is effective in healthy subjects treated with the IL-1 beta blocking antibody, canakinumab: Results of an open …

A Chioato, E Noseda, SD Felix, M Stevens… - Clinical and Vaccine …, 2010 - Am Soc Microbiol

[CITATION][C] Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects Exposed to Secukinumab 150 Mg: Preliminary Study Results.

A Chioato - ARTHRITIS AND RHEUMATISM, 2011 - … , 350 MAIN ST, MALDEN 02148, MA …